Views & Analysis Merck KGaA's bold new approach to cancer immunotherapy Germany’s Merck KGaA is hoping to stand out from the crowd with a bold new approach to cancer immunotherapy.
Oncology Hernexeos and what’s next, with Vicky Brown At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent approval for Hernexeos in NSCLC.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
